Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment

Mount Sinai Journal of Medicine

Volumn 76, Issue 6, 2009, Pages 557-566

  DiFeo, Analisa ^a   Narla, Goutham ^a   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Kruppel like factor 6; Kruppel like factor 6 splice variant 1; Molecular pathogenesis; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; KRUPPEL LIKE FACTOR 6; KRUPPEL LIKE FACTOR 6 SPLICE VARIANT 1; SMALL INTERFERING KRUPPEL LIKE FACTOR 6 SPLICE VARIANT 1; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

APOPTOSIS; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SPECIFICITY; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG EFFICACY; GENE FREQUENCY; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LOSS OF HETEROZYGOSITY; MICE; OVARIAN NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 73349137289     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20150     Document Type: Review

References (59)

1. Jemal A, Siegel R,Ward E, et al. CA Cancer J Clin 2009; 59: 225-249.
2. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001; 276: 34355-34358.
3. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-160.
4. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294: 2563-2566.
5. Chen C, Hytinen ER, Sun X, et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003; 162: 1349-1354.
6. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004; 126: 1090-1103.
7. Ito G, Uchiyama M, Kondo M, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004; 64: 3838-3843.
8. Cho YG, Kim CJ, Park CH, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 2005; 24: 4588-4590.
9. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003; 105: 625-629.
10. Camacho-Vanegas O, Narla G, Teixeira MS, et al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer 2007; 121: 1390-1395.
11. Chen HK, Liu XQ, Lin J, et al. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas [in Chinese]. Ai Zheng 2002; 21: 1047-1050.
12. Tal-Kremer S, Reeves HL, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppellike factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004; 40: 1047-1052.
13. Wang S, Chen X, Zhang W, Qiu F. KLF6 mRNA expression in primary hepatocellular carcinoma. J Huazhong Univ Sci Technol Med Sci 2004; 24: 585-587.
14. Kremer-Tal S, Narla G, Chen Y, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46: 645-654.
15. Peng D, Sheta EA, Powell SM, et al. Alterations in Barrett's-related adenocarcinomas: a proteomic approach. Int J Cancer 2008; 1226: 1303-1310.
16. Narla G, DiFeo A, Reeves HL, et al. A germline DNA polymorphism associated with increased prostate cancer risk enhances alternative splicing of the KLF6 tumor suppressor gene. Cancer Res 2005; 65: 1213-1222.
17. Teixeira MS, Camacho-Vanegas O, Fernandez Y, et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int J Cancer 2007; 121: 1976-1983.
18. DiFeo A, Feld L, Rodriguez E, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 2008; 68: 965-970.
19. Narla G, DiFeo A, Fernandez Y, et al. KLF6-SV1 over-expression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008; 118: 2711-2712.
20. Taetle R, Aickin M, Yang JM, et al. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 1999; 25: 290-300.
21. Höglund M, Gisselsson D, Hansen GB, et al. Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res 2003; 63: 3378-3385.
22. Gorringe KL, Jacobs S, Thompson ER, et al. Highresolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007; 13: 4731-4739.
23. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008; 5: 577-587.
24. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008; 18: 538-548.
25. Berchuck A, Iversen ES, Lancaster JM, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004; 190: 910-925.
26. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11: 3686-3696.
27. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005; 11: 2149-2155. 28. Lancaster JM, Dressman HK, Whitaker RS, et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004; 11: 51-59.
28. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-4710.
29. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25: 517-525.
30. Helleman J, Jansen MP, Span PN, et al. Molecular pro-filing of platinum resistant ovarian cancer. Int J Cancer 2006; 118: 1963-1971.
31. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 2004; 154: 63-66.
32. Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005; 23: 7911-7918.
33. Brown GJ, St John DJ, Macrae FA, Aittomäki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001; 80: 346-349.
34. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-1372.
35. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
36. Bosze P, Bast RC, Berchuck A, et al. Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the consensus meeting organized by the European Society of Gynaecological Oncology. Eur J Gynaecol Oncol 2000; 21: 513-526.
37. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560-570.
38. Rebbeck TR, Lynch HT, Neuhausen SL, et al., for the Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
39. Kauff ND, Satagopan JM, Robson ME, et al. Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
40. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl JMed 2006; 354: 261-269.
41. Finch A, Beiner M, Lubinski J, et al. Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296: 185-192.
42. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 44. Rabban JT, Bell DA. Current issues in the pathology of ovarian cancer. J Reprod Med 2005; 50: 467-467.
43. Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoterbinding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 1998; 273: 33750-33758.
44. Koritschoner NP, Bocco JL, Panzetta-Dutari GM, et al. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem 1997; 272: 9573-9580.
45. El Rouby S, Rao PH, Newcomb EW. Assignment of the human B-cell-derived (BCD1) proto-oncogene to 10p14-p15. Genomics 1997; 43: 395-397.
46. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005; 65: 5761-5768.
47. DiFeo A, Narla G, Hirshfeld J, et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12: 3730-3739.
48. Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 1997; 28: 922-928.
49. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008; 25: 643-655.
50. DiFeo A, Narla G, Camacho-Vanegas O, et al. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 2006; 25: 6026-6031.
51. Dedrick R, Myers C, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11.
52. Trimble EL, Thompson S, Christian MC, Minasian L. Intraperitoneal chemotherapy for women with epithelial ovarian cancer. Oncologist 2008; 13: 403-409.
53. Macleod K, Mullen P, Sewell J, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005; 65: 6789-6800.
54. Difeo A, Huang F, Sangodkar J, et al. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res 2009; 69: 4733-4741.
55. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007; 117: 3612-3614.
56. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
57. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
58. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-11920.
59. Pai SI, Lin YY, Macaes B, et al. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13: 464-477.